BETRF BetterLife Pharma Inc. IFRS
Pharmaceutical Preparations · OTC · SEC CIK 1464165 · Reporting currency CAD · Fiscal year ends 01/31
Financial factors as of 2025-01-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2020Q12019-04-30 · CAD | 2019Q32018-10-31 · USD | 2019Q22018-07-31 · USD | 2018Q12018-04-30 · USD | 2018Q32017-10-31 · USD | 2018Q3*2017-10-30 · USD | 2018Q22017-07-31 · USD | 2018Q12017-04-30 · USD |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | 59,487 | $65,029 | $86,781 | $85,293 | — | — | — | — |
| SG&A expense | 506,786 | $432,112 | $427,753 | $749,415 | $50,480 | $50,480 | $75,641 | $53,289 |
| Operating income | -1.66M | -$1.41M | -$1.18M | -$1.45M | -$184,658 | -$184,658 | -$248,755 | -$285,518 |
| Interest expense | 239,728 | $134,851 | $96,962 | $67,665 | $7,331 | $7,327 | $8,365 | $8,789 |
| Net income | -1.87M | -$3.38M | -$1.41M | -$1.62M | $530,726 | $530,730 | -$5,556 | -$319,812 |
| EPS (basic) | -0.02 | -0.04 | -0.02 | -0.02 | 0.01 | — | 0.00 | 0.00 |
| EPS (diluted) | -0.02 | -0.04 | -0.02 | -0.02 | 0.01 | — | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 99.54M | 89.63M | 85.36M | 86.21M | 81.60M | — | 75.74M | 75.65M |
| Banking | ||||||||
| Net interest income | — | $2,923 | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | 45,414 | $406,901 | $474,491 | $1.51M | $250,386 | $250,386 | $9,943 | $46,698 |
| Inventory | — | $6,795 | — | — | — | — | — | — |
| Current assets | 193,847 | $556,024 | $676,865 | $1.66M | $295,912 | — | $33,138 | $63,502 |
| PP&E, netmay include right-of-use assets (IFRS) | — | $3,404 | $3,641 | $3,879 | — | — | — | — |
| Intangibles | 8.26M | $6.52M | $6.71M | $6.95M | $239,247 | — | — | — |
| Total assets | 9.55M | $7.08M | $7.59M | $8.81M | $535,159 | — | $36,038 | $66,402 |
| Current liabilities | 5.32M | $3.65M | — | — | $150,025 | — | $1.32M | $1.80M |
| Total liabilities | 6.18M | $3.65M | $4.29M | $4.22M | $352,222 | — | $1.32M | $1.80M |
| Shareholders' equity | 3.37M | $3.43M | $3.30M | $4.59M | $182,937 | — | -$1.28M | -$1.73M |
| Shares outstanding | 105.94M | 95.83M | 88.50M | 88.06M | 79.60M | — | 75.85M | 75.65M |
| Cash flow statement | ||||||||
| Operating cash flow | -567,811 | -$705,895 | -$982,799 | -$1.87M | — | -$70,689 | -$38,540 | -$64,982 |
| Investing cash flow | — | -$326,666 | $0 | -$333,333 | — | — | — | — |
| Financing cash flow | 526,000 | $998,394 | -$84,774 | $3.67M | — | $307,125 | $22,500 | $3,000 |
| Stock-based compensation | 5,896 | — | — | 34,898CAD | — | — | — | $417 |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.